Altimmune's pemvidutide granted FDA Fast Track designation for NASH treatment.

Global Banking News-October 26, 2023-Altimmune's pemvidutide granted FDA Fast Track designation for NASH treatment

(C)2023 ENPublishing - http://www.enpublishing.co.uk

Clinical-stage biopharmaceutical company Altimmune Inc (Nasdaq:ALT) said on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its clinical programme for pemvidutide as a potential treatment for Non-Alcoholic Steatohepatitis (NASH).

NASH is a serious and life-threatening condition, a leading cause of global liver failure and transplantation, with no approved treatments available.

Fast Track designation is aimed at expediting the development and review of drugs addressing critical medical needs. Altimmune's Phase 1b study demonstrated significant reductions in liver fat and hepatic inflammation markers for pemvidutide.

...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT